Suppr超能文献

X连锁淋巴增殖性疾病(XLP1)的自然史:来自一位长期幸存者的经验教训。

The Natural History of X-Linked Lymphoproliferative Disease (XLP1): Lessons from a Long-Term Survivor.

作者信息

Jiang Yike, Firan Mihail, Nandiwada Sarada L, Reyes Anaid, Marsh Rebecca A, Vogel Tiphanie P, Hajjar Joud

机构信息

Texas Children's Hospital and Baylor College of Medicine, Department of Pediatrics, Section of Rheumatology, Houston, TX, USA.

Texas Children's Hospital and Baylor College of Medicine, Department of Pathology and Immunology, Houston, TX, USA.

出版信息

Case Reports Immunol. 2020 Aug 26;2020:8841571. doi: 10.1155/2020/8841571. eCollection 2020.

Abstract

X-linked lymphoproliferative disease (XLP1) is a rare primary immunodeficiency characterized by EBV-triggered immune dysregulation, lymphoproliferation, dysgammaglobulinemia, and lymphoma. Early childhood mortality from overwhelming inflammation is expected in most patients. The only curative therapy is hematopoietic stem cell transplant (HSCT); however, whether to perform HSCT on an asymptomatic patient remains debatable. This uncertainty arises because the natural history of XLP1 patients without transplantation is not clear. In this case report, we present the natural history of XLP1 in a 43-year-old male patient who did not receive HSCT. We also review the literature on untransplanted XLP1 patients who lived into mid-adulthood. Despite surviving childhood presentations that are typically fatal, we found that these rare patients remain susceptible to manifestations of XLP1 decades later.

摘要

X连锁淋巴增殖性疾病(XLP1)是一种罕见的原发性免疫缺陷病,其特征为EB病毒引发的免疫失调、淋巴细胞增殖、免疫球蛋白异常血症和淋巴瘤。大多数患者预计会因严重炎症在幼儿期死亡。唯一的治愈性疗法是造血干细胞移植(HSCT);然而,对于无症状患者是否进行HSCT仍存在争议。这种不确定性的产生是因为未接受移植的XLP1患者的自然病程尚不清楚。在本病例报告中,我们呈现了一名43岁未接受HSCT的男性XLP1患者的自然病程。我们还回顾了关于活到中年的未接受移植的XLP1患者的文献。尽管在通常致命的儿童期表现中存活下来,但我们发现这些罕见患者在数十年后仍易出现XLP1的表现。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/971e/7474360/aac93959123c/CRII2020-8841571.001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验